About this book:

Revvity traces its origins to 1937 when Richard Perkin and Charles Elmer founded Perkin-Elmer, a precision optics partnership that quickly became a critical supplier for the U.S. war effort and pioneered commercial infrared spectroscopy with the Model 12 spectrometer. The post-war era saw the company diversify into analytical instrumentation—introducing gas chromatography and atomic absorption spectroscopy—while expanding globally and listing on the NYSE in 1960. A pivotal strategic shift occurred in the 1970s with the invention of the Micralign projection mask aligner, which revolutionized semiconductor manufacturing and established Perkin-Elmer as a dominant force in that sector, alongside acquisitions in computing (Interdata, Wangco) that anticipated the digital integration of laboratory science.

The 1990s marked a transformative pivot toward life sciences through the acquisition of Cetus Corporation’s PCR business and Applied Biosystems, positioning the company at the forefront of the genomics revolution and the Human Genome Project. This era also brought significant crisis, notably the Hubble Space Telescope mirror flaw, which tested the company’s engineering resilience and led to a successful corrective optics solution. Recognizing the divergent trajectories of its businesses, Perkin-Elmer executed a landmark corporate restructuring in 1999, splitting into two public entities: PE Corporation (focused on life sciences) and EG&G, which rebranded as PerkinElmer, Inc., concentrating on analytical instruments, diagnostics, and environmental health.

Throughout the 2000s, PerkinElmer, Inc. solidified its position through disciplined financial management, strategic acquisitions in diagnostics and environmental monitoring, and a deepening commitment to corporate responsibility, sustainability, and philanthropy. This sustained growth, innovation, and market leadership culminated in its inclusion in the S&P 500. In 2023, the company rebranded as Revvity—evoking "revolution" and "velocity"—to reflect a sharpened focus on life sciences and diagnostics. Today, Revvity leverages its legacy of precision measurement to drive emerging frontiers in single-cell analysis, spatial biology, AI-driven bioinformatics, and precision medicine, operating as a global citizen committed to improving health for people and the planet.

What You'll Find Inside:

• Revvity traces its roots to Perkin-Elmer, founded in 1937 on precision optics and a founding ethos of scientific curiosity and innovation.
• The company pioneered key analytical technologies—from the first commercial IR spectrometer and atomic absorption spectrophotometer to PCR and DNA sequencing tools that powered the Human Genome Project.
• Strategic diversification through acquisitions and divestitures (semiconductor equipment, life sciences, diagnostics) continually reshaped its portfolio and fueled sustained growth.
• Global expansion established international manufacturing, service networks, and collaborations, advancing health, environmental monitoring, and space exploration worldwide.
• Disciplined leadership, crisis resilience (e.g., Hubble mirror correction), and relentless R&D investment enabled financial strength and eventual inclusion in the S&P 500.

Who's It For:

This book is ideal for business leaders and strategists seeking insights into long-term corporate innovation and adaptive growth, as well as historians of science and technology interested in the evolution of an S&P 500 enterprise. It will also benefit students, researchers, and investors who want to understand how scientific breakthroughs, strategic acquisitions, and responsible leadership combine to create enduring market value and societal impact.